Earnings calls

Aarti Drugs concall ledger

Every earnings call for AARTIDRUGS — management tone, guidance, KPIs and promise tracking, quarter by quarter.

AARTIDRUGS · 6 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 18 May 2026Call held 18 May 2026

AARTIDRUGS Q4 FY26 Earnings Call Transcript & Analysis

Revenue₹721.1 cr+6% YoYEBITDA₹96.6 cr+2% YoYEBITDA Margin13.4%PAT₹55.3 cr−12% YoYPAT Margin7.7%

Revenue ₹721 cr (+6% YoY); EBITDA ₹97 cr (+2% YoY); EBITDA Margin 13.4%. Q4 FY26 Revenue at INR721.1 crores, reflecting 6% YoY and 20% QoQ growth.

Read full transcript & analysis

Q3 FY26Published 04 Feb 2026Call held 04 Feb 2026

AARTIDRUGS Q3 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue₹602.9 cr+8% YoYConsolidated EBITDA₹56.3 cr−10% YoYConsolidated EBITDA Margin9.3%Consolidated PAT₹40.5 cr+58% YoYConsolidated PAT Margin6.7%

Consolidated Revenue ₹603 cr (+8% YoY); Consolidated EBITDA ₹56 cr (−10% YoY); Consolidated EBITDA Margin 9.3%. Consolidated Revenue grew 8% YoY to INR602.9 crores in Q3 FY26.

Read full transcript & analysis

Q2 FY26Published 10 Nov 2025Call held 10 Nov 2025

AARTIDRUGS Q2 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue₹652.9 cr+9% YoYConsolidated EBITDA₹84.4 cr+23% YoYConsolidated EBITDA Margin12.9%Consolidated PAT₹45.2 cr+29% YoYConsolidated PAT Margin6.9%

Consolidated Revenue ₹653 cr (+9% YoY); Consolidated EBITDA ₹84 cr (+23% YoY); Consolidated EBITDA Margin 12.9%. Q2 FY26 Consolidated Revenue of ₹652.9 crores, up 9% YoY.

Read full transcript & analysis

Q4 FY25Published 21 Jul 2025Call held 21 Jul 2025

AARTIDRUGS Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹591 cr+6% YoYEBITDA₹74 cr+12% YoYEBITDA Margin12.6%

Revenue ₹591 cr (+6% YoY); EBITDA ₹74 cr (+12% YoY); EBITDA Margin 12.6%. Total revenues grew by 6% year-on-year to INR591 crores in Q1 FY26.

Read full transcript & analysis

Q3 FY25Published 30 Jan 2025Call held 30 Jan 2025

AARTIDRUGS Q3 FY25 Earnings Call Transcript & Analysis

Revenue₹568 cr−6% YoY

Revenue ₹568 cr (−6% YoY). Revenue for Q3 FY25 stood at INR568 crores, a 6% decline compared to INR607 crores in Q3 FY24.

Read full transcript & analysis

Q2 FY25Published 02 Nov 2024Call held 02 Nov 2024

AARTIDRUGS Q2 FY25 Earnings Call Transcript & Analysis

Standalone Revenue₹543.1 cr−6% YoYEBITDA₹68.5 crEBITDA Margin11.5%PAT₹35 cr

Standalone Revenue ₹543 cr (−6% YoY); EBITDA ₹68 cr; EBITDA Margin 11.5%. Standalone revenue for Q2 FY25 stood at INR 543.1 crores, a 6% decline YoY.

Read full transcript & analysis